IP Library › Granted Patent US 12,257,288
Granted Patent B2
US 12,257,288 · App. 16/464,105 · Granted Mar 25, 2025

Methods of inducing immune tolerance to clotting factors

Inventors: Jennifer Dumont (Waltham, MA); Nisha Jain (Waltham, MA); Stefan Lethagen (Stockholm, SE)
Assignees: BIOVERATIV THERAPEUTICS INC.; SWEDISH ORPHAN BIOVITRUM AB
A61K38/37A61K38/4846A61P7/04C12Y304/21022C07K2319/21C07K2319/30C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,288
App. No.
16/464,105
Granted
Mar 25, 2025
Kind
B2
Abstract

The present disclosure provides methods inducing immune tolerance in a human, comprising administering to the human an effective amount of a composition or a chimeric protein comprising a clotting factor and an Fc region.

Claims (29)

1. A method of treating a human with hemophilia A who has developed an inhibitory response to factor VIII (FVIII), the method comprising the following steps:

(a) identifying a human subject who has hemophilia A and who has failed to respond to one or more previous immune tolerance therapies against FVIII,

(b) administering between 85 IU/kg and 300 IU/kg of a chimeric protein comprising a FVIII and an Fc region (FVIII-Fc) daily to the human subject for a period sufficient to induce immune tolerance; and

(c) following induction of immune tolerance, administering a tapering regimen of the chimeric protein to the human; and

(d) following the tapering regimen, administering a prophylactic dose of the chimeric protein to the human;

thereby reducing or eliminating an inhibitory immune response to FVIII.

2. The method of claim 1 , wherein the immune tolerance is observed when titer of inhibitory antibodies in the human is less than about 0.6 Bethesda units (BU).

3. The method of claim 1 , wherein the tapering regimen comprises administering a tapering dose of about 50 IU/kg to about 100 IU/kg of the chimeric protein.

4. The method of claim 3 , wherein the tapering dose is administered once a day, once every other day, or three times every week.

5. The method of claim 3 , wherein the tapering dose is administered for about 1 to 32 weeks.

6. The method of claim 1 , wherein the tapering regimen comprises administering a tapering dose of the chimeric protein of about 50 IU/kg once a day from week 1 to week 6 following immune tolerance, or administering a tapering dose of the chimeric protein of about 100 IU/kg once a day from week 1 to week 6 following immune tolerance.

7. The method of claim 6 , wherein the tapering regimen further comprises administering a tapering dose of the chimeric protein of about 50 IU/kg or about 100 IU/kg once every other day from week 6 to week 12 following immune tolerance, and/or administering a tapering dose of the chimeric protein of about 50 IU/kg or about 100 IU/kg once every other day from week 12 to week 16.

8. The method of claim 1 , further comprising administering a prophylactic dose of the chimeric protein following the tapering regimen.

9. The method of claim 1 , wherein time to immune tolerance is less than about 24 weeks.

10. The method of claim 1 , wherein the clotting factor of the FVIII-Fc comprises a B domain deleted FVIII.

11. The method of claim 1 , wherein the human has failed to respond to two previous immune tolerance therapies.

12. The method of claim 1 , wherein the human has failed to respond to five previous immune tolerance therapies.

13. The method of claim 1 , wherein the previous immune tolerance therapy comprises administration of one or more immunosuppressants.

14. The method of claim 1 , wherein the previous immune tolerance therapy comprises a Malmo Regimen or a Bonn Protocol.

15. A method of treating a human with severe hemophilia A who has developed an inhibitory response to factor VIII (FVIII), the method comprising the following steps:

(a) identifying a human subject who has severe hemophilia A and a historical inhibitor peak greater than or equal to (≥) 5 Bethesda units per milliliter (BU/mL), and who has failed to respond to one or more previous immune tolerance therapies against FVIII

b) administering between 85 IU/kg and 300 IU/kg of a chimeric protein comprising a FVIII and an Fc region (FVIII-Fc) daily to the human subject for a period sufficient to induce immune tolerance; and

(c) following induction of immune tolerance, administering a tapering regimen of the chimeric protein to the human subject; and

(d) following the tapering regimen, administering a prophylactic dose of the chimeric protein to the human subject;

thereby reducing or eliminating an inhibitory immune response to FVIII, wherein the human subject was diagnosed as having developed an inhibitor against FVIII at least about 24 months prior to the administering in step (b).

16. The method of claim 15 , wherein the human was diagnosed as having developed an inhibitor against FVIII at least about five years prior to the administering in step (1).

17. The method of claim 15 , wherein the tapering dose is administered for at least 6 weeks.

18. The method of claim 15 , wherein the time to tolerance is less than 15 weeks.

19. The method of claim 15 , wherein the human has a family history for developing an inhibitor immune response.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: DUMONT, JENNIFER; JAIN, NISHA
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 069966/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: DUMONT, JENNIFER; JAIN, NISHA
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 069966/0209 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: DUMONT, JENNIFER; JAIN, NISHA
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 069966/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: DUMONT, JENNIFER; JAIN, NISHA
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 069966/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: DUMONT, JENNIFER; JAIN, NISHA
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 069966/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: DUMONT, JENNIFER; JAIN, NISHA
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 069966/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2025
From: LETHAGEN, STEFAN
To: SWEDISH ORPHAN BIOVITRUM AB
Reel/Frame 069966/0591 →
Continuity (6)
Provisional Application 62582829 · Nov 7, 2017
Provisional Application 62558790 · Sep 14, 2017
Provisional Application 62529866 · Jul 7, 2017
Provisional Application 62466937 · Mar 3, 2017
Provisional Application 62429516 · Dec 2, 2016
Related Publication 20200085915A1 · Mar 19, 2020
References Cited (400)
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4695199A · Goodacre et al. · 1987 [cited by applicant]
US 4704362A · Itakura et al. · 1987 [cited by applicant]
US 4757006A · Toole et al. · 1988 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4868112A · Toole, Jr. · 1989 [cited by applicant]
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 4994371A · Davie et al. · 1991 [cited by applicant]
US 5004803A · Kaufman et al. · 1991 [cited by applicant]
US 5112950A · Meulien et al. · 1992 [cited by applicant]
US 5171844A · Van Ooyen et al. · 1992 [cited by applicant]
US 5364771A · Lollar et al. · 1994 [cited by applicant]
US 5543502A · Nordfang et al. · 1996 [cited by applicant]
US 5595886A · Chapman et al. · 1997 [cited by applicant]
US 5610278A · Nordfang et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5658570A · Newman et al. · 1997 [cited by applicant]
US 5712122A · Boime et al. · 1998 [cited by applicant]
US 5736137A · Anderson et al. · 1998 [cited by applicant]
US 5739277A · Presta et al. · 1998 [cited by applicant]
US 5789203A · Chapman et al. · 1998 [cited by applicant]
US 5834250A · Wells et al. · 1998 [cited by applicant]
US 5846951A · Gregoriadis · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5972885A · Spira et al. · 1999 [cited by applicant]
US 6030613A · Blumberg et al. · 2000 [cited by applicant]
US 6048720A · Dalborg et al. · 2000 [cited by applicant]
US 6060447A · Chapman et al. · 2000 [cited by applicant]
US 6086875A · Blumberg et al. · 2000 [cited by applicant]
US 6096871A · Presta et al. · 2000 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6159730A · Reff · 2000 [cited by applicant]
US 6193980B1 · Efstathiou et al. · 2001 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6228620B1 · Chapman et al. · 2001 [cited by applicant]
US 6242195B1 · Idusogie et al. · 2001 [cited by applicant]
US 6251632B1 · Lillicrap et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6316226B1 · Van Ooyen et al. · 2001 [cited by applicant]
US 6346513B1 · Van Ooyen et al. · 2002 [cited by applicant]
US 6376463B1 · Lollar et al. · 2002 [cited by applicant]
US 6413777B1 · Reff et al. · 2002 [cited by applicant]
US 6458563B1 · Lollar · 2002 [cited by applicant]
US 6485726B1 · Blumberg et al. · 2002 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 6538124B1 · Idusogie et al. · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6821505B2 · Ward · 2004 [cited by applicant]
US 6998253B1 · Presta et al. · 2006 [cited by applicant]
US 7041635B2 · Kim et al. · 2006 [cited by applicant]
US 7083784B2 · Dall'acqua et al. · 2006 [cited by applicant]
US 7199223B2 · Bossard et al. · 2007 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7348004B2 · Peters et al. · 2008 [cited by applicant]
US 7381408B2 · Mezo et al. · 2008 [cited by applicant]
US 7404956B2 · Peters et al. · 2008 [cited by applicant]
US 7632921B2 · Pan et al. · 2009 [cited by applicant]
US 7820162B2 · Mezo et al. · 2010 [cited by applicant]
US 7862820B2 · Peters et al. · 2011 [cited by applicant]
US 8329182B2 · Peters et al. · 2012 [cited by applicant]
US 8759293B2 · Barnett · 2014 [cited by applicant]
US 8815250B2 · Rivera et al. · 2014 [cited by applicant]
US 8932830B2 · Peters et al. · 2015 [cited by applicant]
US 9050318B2 · Dumont et al. · 2015 [cited by applicant]
US 9233145B2 · Pierce et al. · 2016 [cited by applicant]
US 9241978B2 · Dumont et al. · 2016 [cited by applicant]
US 9266145B2 · Maurer et al. · 2016 [cited by applicant]
US 9623091B2 · Pierce et al. · 2017 [cited by applicant]
US 9629903B2 · Pierce et al. · 2017 [cited by applicant]
US 9636416B2 · Peters et al. · 2017 [cited by applicant]
US 9670475B2 · Pierce et al. · 2017 [cited by applicant]
US 9675676B2 · Pierce et al. · 2017 [cited by applicant]
US 9867873B2 · Pierce et al. · 2018 [cited by applicant]
US 10221455B2 · Jiang et al. · 2019 [cited by applicant]
US 10391152B2 · Jiang et al. · 2019 [cited by applicant]
US 10568943B2 · Pierce et al. · 2020 [cited by applicant]
US 10745680B2 · Liu et al. · 2020 [cited by applicant]
US 10881742B2 · Dumont et al. · 2021 [cited by applicant]
US 10898554B1 · Pierce et al. · 2021 [cited by applicant]
US 11225650B2 · Pierce et al. · 2022 [cited by applicant]
US 11266720B2 · Dumont et al. · 2022 [cited by applicant]
US 11286528B2 · Jiang et al. · 2022 [cited by applicant]
US 11642398B2 · Brader et al. · 2023 [cited by applicant]
US 20020038002A1 · Zaghouani et al. · 2002 [cited by applicant]
US 20030211113A1 · Kakkis et al. · 2003 [cited by applicant]
US 20030235536A1 · Blumberg et al. · 2003 [cited by applicant]
US 20040096456A1 · Conti-Fine et al. · 2004 [cited by applicant]
US 20040110929A1 · Bjorn et al. · 2004 [cited by applicant]
US 20050100990A1 · Saenko et al. · 2005 [cited by applicant]
US 20050147618A1 · Rivera et al. · 2005 [cited by applicant]
US 20050260194A1 · Peters et al. · 2005 [cited by applicant]
US 20070231329A1 · Lazar et al. · 2007 [cited by applicant]
US 20070237765A1 · Lazar et al. · 2007 [cited by applicant]
US 20070237766A1 · Lazar et al. · 2007 [cited by applicant]
US 20070237767A1 · Lazar et al. · 2007 [cited by applicant]
US 20070243188A1 · Lazar et al. · 2007 [cited by applicant]
US 20070248603A1 · Lazar et al. · 2007 [cited by applicant]
US 20070286859A1 · Lazar et al. · 2007 [cited by applicant]
US 20080004206A1 · Rosen et al. · 2008 [cited by applicant]
US 20080057056A1 · Lazar et al. · 2008 [cited by applicant]
US 20080153751A1 · Rosen et al. · 2008 [cited by applicant]
US 20080161243A1 · Rosen et al. · 2008 [cited by applicant]
US 20080194481A1 · Rosen et al. · 2008 [cited by applicant]
US 20080261877A1 · Ballance et al. · 2008 [cited by applicant]
US 20090087411A1 · Fares et al. · 2009 [cited by applicant]
US 20090163699A1 · Chamberlain et al. · 2009 [cited by applicant]
US 20090264627A1 · Gillies et al. · 2009 [cited by applicant]
US 20100239554A1 · Schellenberger et al. · 2010 [cited by applicant]
US 20100292130A1 · Skerra et al. · 2010 [cited by applicant]
US 20100323956A1 · Schellenberger et al. · 2010 [cited by applicant]
US 20110046060A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110046061A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110077199A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110159540A1 · Mezo et al. · 2011 [cited by applicant]
US 20110172146A1 · Schellenberger et al. · 2011 [cited by applicant]
US 20110182896A1 · Rivera et al. · 2011 [cited by applicant]
US 20110268737A1 · Favier et al. · 2011 [cited by applicant]
US 20120142593A1 · Zhao et al. · 2012 [cited by applicant]
US 20130108629A1 · Dumont et al. · 2013 [cited by applicant]
US 20130171175A1 · Pierce et al. · 2013 [cited by applicant]
US 20130202595A1 · Pierce et al. · 2013 [cited by applicant]
US 20130274194A1 · Dumont et al. · 2013 [cited by applicant]
US 20140308280A1 · Maloney et al. · 2014 [cited by applicant]
US 20140370035A1 · Jiang · 2014 [cited by examiner]
US 20150023959A1 · Chhabra et al. · 2015 [cited by applicant]
US 20150158929A1 · Schellenberger et al. · 2015 [cited by applicant]
US 20150252345A1 · Pierce et al. · 2015 [cited by applicant]
US 20150266943A1 · Chhabra et al. · 2015 [cited by applicant]
US 20150266944A1 · Jiang et al. · 2015 [cited by applicant]
US 20160199455A1 · Dumont et al. · 2016 [cited by applicant]
US 20160257943A1 · Pierce et al. · 2016 [cited by applicant]
US 20160346365A1 · Pierce et al. · 2016 [cited by applicant]
US 20170226189A1 · Peters et al. · 2017 [cited by applicant]
US 20170266309A1 · Peters et al. · 2017 [cited by applicant]
US 20190241960A1 · Jiang et al. · 2019 [cited by applicant]
CA 2863329A1 · 2013 [cited by applicant]
EP 0154316A2 · 1985 [cited by applicant]
EP 0295597A2 · 1988 [cited by applicant]
EP 0401384A1 · 1990 [cited by applicant]
EP 2173890A1 · 2010 [cited by applicant]
EP 2184070A1 · 2010 [cited by applicant]
EP 2802668A1 · 2014 [cited by applicant]
EP 3453402A1 · 2019 [cited by applicant]
EP EP3548063A1 · 2019 [cited by applicant]
JP 2005530762A · 2005 [cited by applicant]
JP 2007500744A · 2007 [cited by applicant]
JP 2011505414A · 2011 [cited by applicant]
JP 2011523663A · 2011 [cited by applicant]
JP 2012507994A · 2012 [cited by applicant]
JP 2012522490A · 2012 [cited by applicant]
JP 2013510581A · 2013 [cited by applicant]
JP 2013512678A · 2013 [cited by applicant]
JP 2017149784A · 2017 [cited by applicant]
WO WO1987004187A1 · 1987 [cited by applicant]
WO WO1988000831A1 · 1988 [cited by applicant]
WO WO1988003558A1 · 1988 [cited by applicant]
WO WO1988007089A1 · 1988 [cited by applicant]
WO WO1988008035A1 · 1988 [cited by applicant]
WO WO1991009122A1 · 1991 [cited by applicant]
WO WO1992016221A1 · 1992 [cited by applicant]
WO WO1993020093A1 · 1993 [cited by applicant]
WO WO1994011503A2 · 1994 [cited by applicant]
WO WO1995034326A1 · 1995 [cited by applicant]
WO WO1996014339A1 · 1996 [cited by applicant]
WO WO1998005787A1 · 1998 [cited by applicant]
WO WO1998023289A1 · 1998 [cited by applicant]
WO WO1999051642A1 · 1999 [cited by applicant]
WO WO1999058572A1 · 1999 [cited by applicant]
WO WO2000009560A2 · 2000 [cited by applicant]
WO WO2000032767A1 · 2000 [cited by applicant]
WO WO2000042072A2 · 2000 [cited by applicant]
WO WO2002044215A2 · 2002 [cited by applicant]
WO WO2002060919A2 · 2002 [cited by applicant]
WO WO2003074569A2 · 2003 [cited by applicant]
WO WO2003077834A2 · 2003 [cited by applicant]
WO WO2004016750A2 · 2004 [cited by applicant]
WO WO2004029207A2 · 2004 [cited by applicant]
WO WO2004035752A2 · 2004 [cited by applicant]
WO WO2004044859A1 · 2004 [cited by applicant]
WO WO2004063351A2 · 2004 [cited by applicant]
WO WO2004074455A2 · 2004 [cited by applicant]
WO WO2004099249A2 · 2004 [cited by applicant]
WO WO2004101739A2 · 2004 [cited by applicant]
WO WO2004101740A2 · 2004 [cited by applicant]
WO WO2005001025A2 · 2005 [cited by applicant]
WO WO2005040217A2 · 2005 [cited by applicant]
WO WO2005047327A2 · 2005 [cited by applicant]
WO WO2005070963A1 · 2005 [cited by applicant]
WO WO2005077981A2 · 2005 [cited by applicant]
WO WO2005092925A2 · 2005 [cited by applicant]
WO WO2005123780A2 · 2005 [cited by applicant]
WO WO2006019447A1 · 2006 [cited by applicant]
WO WO2006047350A2 · 2006 [cited by applicant]
WO WO2006074199A1 · 2006 [cited by applicant]
WO WO2006085967A2 · 2006 [cited by applicant]
WO WO2007021494A2 · 2007 [cited by applicant]
WO WO2008033413A2 · 2008 [cited by applicant]
WO WO2008155134A1 · 2008 [cited by applicant]
WO WO2009058322A1 · 2009 [cited by applicant]
WO WO2009071886A1 · 2009 [cited by applicant]
WO WO2009149303A1 · 2009 [cited by applicant]
WO WO2010006635A1 · 2010 [cited by applicant]
WO WO2010052228A1 · 2010 [cited by applicant]
WO WO2010091122A1 · 2010 [cited by applicant]
WO WO2010111414A1 · 2010 [cited by applicant]
WO WO2010144502A2 · 2010 [cited by applicant]
WO WO2010144508A1 · 2010 [cited by applicant]
WO WO2011028228A1 · 2011 [cited by applicant]
WO WO2011028229A1 · 2011 [cited by applicant]
WO WO2011028344A2 · 2011 [cited by applicant]
WO WO2011060242A2 · 2011 [cited by applicant]
WO WO2011069164A2 · 2011 [cited by examiner]
WO WO2012006623A2 · 2012 [cited by applicant]
WO WO2013009627A2 · 2013 [cited by examiner]
WO WO2013106789A1 · 2013 [cited by examiner]
WO WO2015106052A1 · 2015 [cited by applicant]
WO WO2018102760A1 · 2018 [cited by applicant]
Kempton, C.L. and White, G.C. Blood;13(1):11-17 (Year: 2009). [cited by examiner]
(Jan. 2017) “ELOCTATE® Package Insert”, Retrieved from: « http://worldwideweb.eloctate.com/_assets/pdf/ELOCTATE PI_January2017.pdf.». [cited by applicant]
(Feb. 28-Mar. 2, 2006) “Report of Expert Meeting on FVIII Products and Inhibitor Development”, European Medicine Agency, 32 Pages. [cited by applicant]
Armour, et al. (Aug. 1999) “Recombinant Human IgG Molecules Lacking Fcgamma Receptor I Binding and Monocyte Triggering Activities”, European Journal of Immunology, vol. 29, No. 8, pp. 2613-2624. [cited by applicant]
Astermark, et al. (Dec. 1, 2006) “Polymorphisms in the TNFA Gene and the Risk of Inhibitor Development in Patients with Hemophilia A”, Hemostasis, Thrombosis, and Vascular Biology, Blood, vol. 108, No. 12, pp. 3739-3745. [cited by applicant]
Bai, et al. (May 17, 2005) “Recombinant Granulocyte Colony-Stimulating Factor-Transferrin Fusion Protein as An Oral Myelopoietic Agent”, Proceedings of the National Academy of Sciences of the United States of America, v… [cited by applicant]
Batsuli, et al. (Apr. 26, 2016) “Innovating Immune Tolerance Induction for Haemophilia”, Haemophilia, vol. 22, Suppl. 5, pp. 31-35. [cited by applicant]
Benhar, et al. (Dec. 1994) “Cloning, Expression and Characterization of The Fv Fragments of The Anti-Carbohydrate mAbs BI and B5 As Single-Chain Immunotoxins”, Protein Engineering, Design and Selection, vol. 7, No. 12, … [cited by applicant]
Bovenschen, et al. (2005) “LDL Receptor Cooperates with LDL Receptor-Related Protein in Regulating Plasma Levels of Coagulation Factor VIII In vivo”, Blood, vol. 106, pp. 906-912. [cited by applicant]
Bovenschen, Niels (2010) “LDL Receptor Polymorphisms Revisited”, Blood, vol. 116, No. 25, pp. 5439-5440. [cited by applicant]
Brandsma, et al. (Mar.-Apr. 2011) “Recombinant Human Transferrin: Beyond Iron Binding and Transport”, Biotechnology Advances, vol. 29, No. 2, pp. 230-238. [cited by applicant]
Burmeister, et al. (Nov. 24, 1994) “Crystal Structure of The Complex of Rat Neonatal Fc Receptor with Fc”, Nature, vol. 372, No. 6504, pp. 379-383. [cited by applicant]
Cameron, et al. (Feb. 1998) “The Canine Factor VIII cDNA and 5' Flanking Sequence”, Journal of Thrombosis and Haemostasis, vol. 79, No. 2, pp. 317-322. [cited by applicant]
Capon, et al. (Feb. 9, 1989) “Designing CD4 Immunoadhesins For AIDS Therapy”, Nature, vol. 337, No. 6207, pp. 525-531. [cited by applicant]
Dennis, et al. (Sep. 20, 2002) “Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins”, Journal of Biological Chemistry, vol. 277, No. 38, pp. 35035-35043. [cited by applicant]
Dobeli, et al. (1988) “Role of The Carboxy-Terminal Sequence on The Biological Activity of Human Immune Interferon (IFN-y)”, Journal of Biotechnology, vol. 7, No. 3, pp. 199-216. [cited by applicant]
Eaton, et al. (Dec. 1986) “Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule”, Biochemistry, vol. 25, No. 26, pp. 8343-8347. [cited by applicant]
Francis, G E. (1992) “Protein Modification and Fusion Proteins”, Focus on Growth Factors, vol. 3, No. 2, Mediscript, England, pp. 4-10. [cited by applicant]
Friend, et al. (Dec. 15, 1999) “Phase I Study of An Engineered Aglycosylated Humanized Cd3 Antibody in Renal Transplant Rejection1”, Transplantation, vol. 68, Issue 11, pp. 1632-1637. [cited by applicant]
Groomes, et al. (May 2016) “Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction with Recombinant Factor VIII-Fc Fusion Protein”, Pediatric Blood & Cancer, vol. 63, Issue 5, pp. 922-924. [cited by applicant]
Ho, et al. (Apr. 15, 1989) “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction”, Gene, vol. 77, No. 1, pp. 51-59. [cited by applicant]
Hoeben, et al. (1990) “Expression of Functional Factor Viii in Primary Human Skin Fibroblasts After Retrovirus-Mediated Gene Transfer”, Journal of Biological Chemistry, vol. 265, No. 13, pp. 7318-7323. [cited by applicant]
Holstein, et al. (Oct. 15, 2016) “Current View and Outcome of ITI Therapy—A Change Over Time?”, Thrombosis Research, vol. 148, pp. 38-44. [cited by applicant]
Israel, et al. (Sep. 1997) “Expression of The Neonatal Fc Receptor, FcRn, On Human Intestinal Epithelial Cells”, Immunology, vol. 92, No. 1, pp. 69-74. [cited by applicant]
Kasuda, et al. (Aug. 2008) “Establishment of Embryonic Stem Cells Secreting Human Factor VIII for Cell-Based Treatment of Hemophilia A”, Journal of Thrombosis and Haemostasis, vol. 6, No. 8, pp. 1352-1359. [cited by applicant]
Kim, et al. (Sep. 2010) “Transferrin Fusion Technology: a Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides”, Journal of Pharmacology and Experimental Therapeutics, vol. 334, No. 3, pp. 682-69… [cited by applicant]
Kobayashi, et al. (Feb. 2002) “FcRn-Mediated Transcytosis of Immunoglobulin G in Human Renal Proximal Tubular Epithelial Cells”, American Journal of Physiology-Renal Physiology, vol. 282, No. 2, pp. F358-F365. [cited by applicant]
Kraulis, et al. (Jan. 8, 1996) “The Serum Albumin-Binding Domain of Streptococcal Protein G is a Three-Helical Bundle: a Heteronuclear NMR Study”, FEBS Letters, vol. 378, Issue 2, pp. 190-194. [cited by applicant]
Krishnamoorthy, et al. (Mar. 2016) “Recombinant Factor VIII Fc (rFVIIIFc) Fusion Protein Reduces Immunogenicity and Induces Tolerance in Hemophilia a Mice”, Cellular Immunology, vol. 301, pp. 30-39. [cited by applicant]
Langner, et al. (Apr. 1988) “Synthesis of Biologically Active Deletion Mutants of Human Factor VIII:C”, Behring Institute Mitteilungen, No. 82, pp. 16-25. [cited by applicant]
Larrick, et al. (1989) “Rapid Cloning of Rearranged Immunoglobulin Genes from Human Hybridoma Cells using Mixed Primers and the Polymerase Chain Reaction”, Biochemical and Biophysical Research Communications, vol. 160, … [cited by applicant]
Lenting, et al. (May 2010) “The Disappearing Act of Factor VIII”, Haemophilia, vol. 16, No. 102, pp. 6-15. [cited by applicant]
Li, et al. (May 2002) “The Role of The Transferrin-Transferrin-Receptor System in Drug Delivery and Targeting”, Trends in Pharmacological Sciences, vol. 23, No. 5, pp. 206-209. [cited by applicant]
Linhult, et al. (Feb. 2002) “Mutational Analysis of The Interaction Between Albumin-Binding Domain from Streptococcal Protein G and Human Serum Albumin”, Protein Science, vol. 11, No. 2, pp. 206-213. [cited by applicant]
Malec, et al. (Nov. 2016) “Extended Half-Life Factor VIII for Immune Tolerance Induction in Haemophilia”, Haemophilia, vol. 22, Issue 6, pp. e552-e554. [cited by applicant]
Malec, et al. (Dec. 2015) “Immune Tolerance Induction Using Rfviiifc (Eloctate)”, Blood, vol. 126, No. 23, 57th Annual Meeting of the American-Society-of-Hematology, pp. 1-2. [cited by applicant]
Malik, et al. (Sep. 1992) “Polyethylene Glycol (PEG)-Modified Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Conserved Biological Activity”, Experimental Hematology, vol. 20, No. 8, pp. 1028-1035. [cited by applicant]
Mannucci, et al. (Jun. 1, 2001) “The Hemophilias—From Royal Genes to Gene Therapy”, New England Journal of Medicine, vol. 344, No. 23, pp. 1773-1779. [cited by applicant]
Martinelli, et al. (2010) “Polymorphisms at LDLR Locus May Be Associated with Coronary Artery Disease Through Modulation of Coagulation Factor VIII Activity and Independently from Lipid Profile”, Blood, vol. 116, pp. 56… [cited by applicant]
Mei, et al. (Jul. 15, 2010) “Rational Design of a Fully Active, Long-Acting PEGylated Factor VIII for Hemophilia A Treatment”, Blood, vol. 116, No. 2, pp. 270-279. [cited by applicant]
Meulien, et al. (1988) “A New Recombinant Procoagulant Protein Derived from the cDNA Encoding Human Factor Viii”, Protein Engineering, Design and Selection, vol. 2, No. 4, pp. 301-306. [cited by applicant]
Miao, et al. (May 1, 2004) “Bioengineering of Coagulation Factor VIII for Improved Secretion”, Blood, vol. 103, No. 9, pp. 3412-3419. [cited by applicant]
Peyvandi, et al. (Jul. 2006) “Genetic Diagnosis of Haemophilia and Other Inherited Bleeding Disorders”, Haemophilia, vol. 12, Suppl 3, pp. 82-89. [cited by applicant]
Pipe, et al. (2011) “Functional Factor VIII Made with Von Willebrand Factor at High Levels in Transgenic Milk”, Journal of Thrombosis and Haemostasis, vol. 9, No. 11, pp. 2235-2242. [cited by applicant]
Ragni, et al. (Sep. 2016) “Inhibitor Development in Two Cousins Receiving Full-Length Factor Viii (Fviii) and FVIII-Fc Fusion Protein”, Hemophilia, vol. 22, Issue 5, pp. e462-e464. [cited by applicant]
Rodriguez-Merchan, et al. (2002) “Inhibitors in Patients with Hemophilia”, Blackwell Science, Ltd. [cited by applicant]
Ron, et al. (1993) “Expression of Biologically Active Recombinant Keratinocyte Growth Factor. Structure/Function Analysis of Amino-Terminal Truncation Mutants”, Journal of Biological Chemistry, vol. 268, No. 4, pp. 2984… [cited by applicant]
Roth, et al. (1993) “Expression of Polysialic Acid in Human Tumors and Its Significance for Tumor Growth”, Polysialic Acid: From Microbes to Man, pp. 335-348. [cited by applicant]
Routledge, et al. (Oct. 1, 1995) “The Effect of Aglycosylation on the Immunogenicity of a Humanized Therapeutic CD3 Monoclonal Antibody”, Transplantation, vol. 60, No. 8, pp. 847-853. [cited by applicant]
Ruberti, et al. (Jul. 12, 1994) “The Use of The RACE Method to Clone Hybridoma cDNA When V Region Primers Fail”, Journal of Immunological Methods, vol. 173, No. 1, pp. 33-39. [cited by applicant]
Sarver, et al. (Dec. 1987) “Stable Expression of Recombinant Factor Viii Molecules Using A Bovine Papillomavirus Vector”, DNA, vol. 6, No. 6, pp. 553-564. [cited by applicant]
Schlapschy, et al. (Jun. 1, 2007) “Fusion of A Recombinant Antibody Fragment with A Homo-Amino-Acid Polymer: Effects on Biophysical Properties and Prolonged Plasma Half-Life”, Protein Engineering, Design and Selection, … [cited by applicant]
Shields, et al. (Mar. 2, 2001) “High Resolution Mapping of The Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to The Fc Gamma R”, Jour… [cited by applicant]
Story, et al. (Dec. 1, 1994) “A Major Histocompatibility Complex Class I-like Fc Receptor Cloned from Human Placenta: Possible Role in Transfer of Immunoglobulin G from Mother to Fetus”, Journal of Experimental Medicine… [cited by applicant]
Toole, et al. (Aug. 1986) “A Large Region (Approximately Equal to 95 kDa) Of Human Factor VIII is Dispensable for In Vitro Procoagulant Activity”, Proceedings of the National Academy of Sciences, vol. 83, No. 16, pp. 59… [cited by applicant]
Wang, et al. (Nov. 7, 2011) “Receptor-Mediated Activation of a Proinsulin-Transferrin Fusion Protein in Hepatoma Cells”, Journal of Controlled Release, vol. 155, No. 3, pp. 386-392. [cited by applicant]
Ward, et al. (Apr. 1995) “The Effector Functions of Immunoglobulins: Implications for Therapy”, Therapeutic immunology, vol. 2, No. 2, pp. 77-94. [cited by applicant]
Cutler, et al. (2002) “The Identification and Classification of 41 Novel Mutations in The Factor VIII Gene (F8c)”, Human Mutation, vol. 19, No. 3, pp. 274-278. [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “Human transferrin mRNA, complete cds,” Accession No. M12530, accessed at https://www.ncbi.nlm.nih.gov/nuccore/339452/, accessed on Jan. 1, 2018, 2 pages. [cited by applicant]
Genbank, “Transferrin [human, liver, mRNA, 2347 nt],” Accession No. S95936, accessed at https://www.ncbi.nlm.nih.gov/nuccore/595936, accessed on Jan. 1, 2018, 2 pages. [cited by applicant]
Holt, et al. (May 2008) “Anti-Serum Albumin Domain Antibodies for Extending the Half-Lives of Short Lived Drugs”, Protein Engineering, Design and Selection, vol. 21, No. 5, pp. 283-288. [cited by applicant]
Horton, et al. (1993) “Gene Splicing by Overlap Extension”, Methods in Enzymology, vol. 217, pp. 270-279. [cited by applicant]
International Search Report & Written Opinion Received for PCT Application No. PCT/US2017/064323, mailed on Mar. 28, 2018. [cited by applicant]
Lillicrap, “Extending half-life in coagulation factors: where do we stand?”, Thrombosis Research. 2008, 122(Suppl. 4): S2-S8. [cited by applicant]
Muller, et al. (Aug. 2007) “Recombinant Bispecific Antibodies for Cellular Cancer Immunotherapy”, Current opinion in molecular therapeutics, vol. 9, No. 4, pp. 319-326. [cited by applicant]
Oldenburg et al., “Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate”, Haemophilia, 2014, 20: 83-91. [cited by applicant]
Roovers, et al. (Mar. 2007) “Efficient Inhibition of EGFR Signaling and of Tumour Growth by Antagonistic anti-EFGR Nanobodies”, Cancer Immunology, Immunotherapy, vol. 56, No. 3, pp. 303-317. [cited by applicant]
Sommermeyer, et al. (1987) “Klinisch Verwendete Hydroxyethylstärke: Physikalischchemische Charakterisierung”, Krankenhauspharmazie, vol. 8, No. 8, Deutscher Apotheker Verlag, Birkenwaldstr, Germany, pp. 271-278. [cited by applicant]
Trussel, et al. (Dec. 2009) “New Strategy for The Extension of The Serum Half-Life of Antibody Fragments”, Bioconjugate Chemistry, vol. 20, No. 12, pp. 2286-2292. [cited by applicant]
Weidler, et al. (May 1991) “Pharmacokinetic Parameters as Criteria for Clinical Use of Hydroxyethyl Starch Preparations”, Arzneimittelforschung/Drug Research, vol. 41, No. 5, pp. 494-498. [cited by applicant]
Akilesh, et al., “Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism,” The Journal of Immunology 179(7):4580-4588, The American Association of Immunologists, Inc., United… [cited by applicant]
Aledort, et al., “A longitudinal study of orthopaedic outcomes for severe factor-VIII deficient haemophiliacs,” Journal of Internal Medicine 236(4):391-399, Blackwell Scientific Publications, England (1994). [cited by applicant]
Armour, et al., “Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activities,” European Journal of Immunology 29(8):2613-2624, Wiley-VCH Verlag GmbH, Germany (1999). [cited by applicant]
Astermark et al., “Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A,” Journal of Thrombosis and Haemostasis 5(2):263-265, International Society on Thrombosis and Haemostasi… [cited by applicant]
Astermark et al., “Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A,” Blood 107(8):3167-3172, The American Society of Hematology, Uni… [cited by applicant]
Astermark et al., (2005) “The Malmö International Brother Study (MIBS): Genetic defects and inhibitor development in siblings with severe hemophilia A”, Haematologica, 90(7): 924-931. [cited by applicant]
Astermark et al., “The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients”, Haemophilia, May 2001, 7(3): 267-272. [cited by applicant]
Astermark, “Immune tolerance induction in patients with haemophilia A”, Thromb Res, Jan. 2011, 127(Suppl 1): S6-S9, Epublished Nov. 5, 2010. [cited by applicant]
Astermark, et al., “Basic Aspects of Inhibitors to Factors VIII and IX and the Influence of Non-Genetic Risk Factors”, J. Haemophilia, vol. 12, Supplement 6, pp. 8-13, Dec. 2006. [cited by applicant]
Aznar, et al., “The orthopaedic status of severe haemophiliacs in Spain,” Haemophilia 6(3):170-176, Blackwell Science, England (2000). [cited by applicant]
Bajaj et al., “Redetermination of the Rate-Limiting Step in the Activation of Factor IX by Factor XIa and by Factor VIIa/Tissue Factor. Explanation for Different Electrophoretic Radioactivity Profiles Obtained on Activa… [cited by applicant]
Bi et al., “Targeted Disruption of the Mouse Factor VIII Gene Produces a Model of Haemophilia A,” Nature Genetics 10(1):119-121, Nature Publishing Co., United States (1995). [cited by applicant]
Bitonti et al., “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway,” Proceedings of the National Academy of Sciences USA 101(26):9763-9768, The N… [cited by applicant]
Borvak et al., “Functional Expression of the MHC Class I-related Receptor, FcRn, in Endothelial Cells of Mice,” International Immunology 10(9):1289-1298, Oxford University Press, i England (1998). [cited by applicant]
Brandstetter et al., “X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B,” Proceedings of the National Academy of Sciences USA 92(21):9796-9800, The Nation… [cited by applicant]
Brunetti-Pierri et al., “Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B,” Human Gene Therapy 20(5):479-485, Mary Ann Liebert. I… [cited by applicant]
Brutlag et al., “Improved sensitivity of biological sequence database searches,” Computer Applications in the Biosciences 6(3):237-245, Oxford University Press, England (1990). [cited by applicant]
Butenas et al., “Blood coagulation,” Biochemistry (Moscow) 67(1):3-12, MAIK Nauka/Interperiodica, United States (2002). [cited by applicant]
Callaghan et al., “Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?”, Haemophilia, May 2011, 17(3): 483-489, Epublished Dec. 1, 2010. [cited by applicant]
Cao, et al., “Role of regulatory T cells in tolerance to coagulation factors,” Journal of Thrombosis and Haemostasis 7(Suppl 1):88-91, Blackwell Publishing, England (2009). [cited by applicant]
Castaman, G., et al., “Pregnancy and Delivery in Women with Von Willebrand's Disease and Different Von Willebrand Factor Mutations,” Haematologica 95(6):963-969, Ferrata Storti Foundation, Italy (2010). [cited by applicant]
Chang, J., et al., “Changing Residue 338 in Human Factor IX from Arginine to Alanine Causes an Increase in Catalytic Activity,” The Journal of Biological Chemistry 273(20):12089-12094, The American Society for Biochemis… [cited by applicant]
Coppola et al., (2009) “Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors”, J Thromb Haemost, 7(11): 1809-1815, doi: 10.1111/… [cited by applicant]
Coppola, A., et al., “Primary Prophylaxis in Children with Haemophilia,” Blood Transfusion Prophylaxis in Congenital Coagulation Disorders 6(Suppl 2):s4-s11, Society of Transfusion Medicine and Immunohaematology, Italy … [cited by applicant]
Damiano et al., (2000) “Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience”, The Tri-Regional Nursing Group, Haemophilia, 6(5): 526-532. [cited by applicant]
De Groot, et al., “Activation of Natural Regulatory T Cells by IgG Fc-Derived Peptide ‘Tregitopes’”, Blood, vol. 112, No. 8, pp. 3303-3311, Oct. 15, 2008. [cited by applicant]
Delignant, “Transplacental Delivery of FC-Fused Recombinant Factor VIII ( [cited by applicant]
Delignant, Abstract—“Transplacental Delivery of FC-Fused Factor VIII ( [cited by applicant]
Dimichele et al., (2002) “The North American Immune Tolerance Registry: practices, outcomes, outcome predictors”, Thromb Haemost, 87(1): 52-57. [cited by applicant]
Dimichele, (2009) “The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy”, Haemophilia, 15(1): 320-328, doi:10.1111/j.1365-2516.2008.01880.x. [cited by applicant]
Dumont, J.A., et al., “Delivery of an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway,” Journal of Aerosol Medicine 18(3):294-303, May Ann Liebert, Inc., United State… [cited by applicant]
Dumont, J.A., et al., “Factor VIII-Fc Fusion Protein Shows Extended Half-Life and Hemostatic Activity in Hemophilia A Dogs,” ASH 51st Annual Meeting Abstracts 114(22): Abstract 545, The American Society of Hematology, U… [cited by applicant]
Dumont, J.A., et al., “Monomeric Fc Fusion Technology: An Approach to Create Long-Lasting Clotting Factors,” in: Therapeutic Proteins- Strategies to Modulate Half-Life, Kontermann R., ed., Chapter 10, pp. 189-206, Wiley… [cited by applicant]
Dumont, J.A., et al., “Monomeric Fc Fusion: Impact on Pharmacokinetic and Biological Activity of Protein Therapeutics,” BioDrugs 20(3): 151-160, Adis Data Information B.V., New Zealand (2006). [cited by applicant]
Dumont, J.A., et al., “Prolonged Activity of a Recombinant Factor VIII-Fc Fusion Protein in Hemophilia a Mice and Dogs,” Blood 119(13):3024-3030, The American Society of Hematology, United States (Mar. 29, 2012). [cited by applicant]
Eckhardt, C.L., et al., “Surgery and inhibitor development in hemophilia A: a systematic review,” Journal of Thrombosis and Haemostasis 9(10):1948-1958, Blackwell Publishing, England (Oct. 2011). [cited by applicant]
Eigenbrot, et al., “The Factor VII Zymogen Structure Reveals Reregistration of ß Strands during Activation”, Structure, vol. 9, No. 7, pp. 627-636, Jul. 3, 2001. [cited by applicant]
EMA European Medicines Agency, “Reflection Paper on Immune Tolerance Induction in haemophilia A patients with inhibitors”, Committee for Medicinal Products for Human Use, Mar. 21, 2013. [cited by applicant]
English language Abstract of European Patent Publication No. EP 0295597 A2, European Patent Office, Espacenet database—Worldwide (1988). [cited by applicant]
Ettingshausen et al., “Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series”, Haemophilia, Jan. 2010, 16(1): 90-100. [cited by applicant]
Extended European Search Report for European Application No. 18183272.6, dated Feb. 13, 2019. [cited by applicant]
Fatouros, A., et al., “Recombinant factor VIII SQ influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution,” International Journal of Pharmaceutics 155(1):121-131, Elsevier, United Sta… [cited by applicant]
Feagan, et al., “Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease”, New England Journal of Medicine, vol. 375, No. 20, pp. 1946-1960, Nov. 17, 2016. [cited by applicant]
Feldman, B.M., et al., “Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study,” Journal of Thrombosis and Haemostasis 4(6):1228-1236, Bl… [cited by applicant]
Foster, P.A., et al., “Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine,” Blood 75(10):1999-2004, The American Soci… [cited by applicant]
Franchini et al., (2011), “Immune tolerance induction for patients with severe hemophilia A: a critical literature review”, J Thromb Thrombolysis, 32(4): 439-447, doi:10.1007/s11239-011-0624-3. [cited by applicant]
Franchini et al., (2013) “Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update”, Semin Thromb Hemost, 39(7): 752-766, doi:… [cited by applicant]
Freiburghaus, et al., “Tolerance Induction Using the Malmö Treatment Model 1982-1995”, Haemophilia, vol. 5, No. 1, pp. 32-39, Jan. 1999. [cited by applicant]
Gayle, R.B., III., et al., “Identification of Regions in Interleukin-Iα Important for Activity,” The Journal of Biological Chemistry 268(29):22105-22111, The American Society for Biochemistry and Molecular Biology, Inc.… [cited by applicant]
GenBank, “Homo sapiens coagulation factor VIII, procoagulant component (F8), transcript variant 1, mRN A,” Accession No. NM_000132.3, accessed at http://www.ncbi.nlm.nih.gov/nuccore/NM_000132.3, 2008, 12 pages. [cited by applicant]
GenBank, “Homo sapiens mRNA for immunoglobulin kappa heavy chain,” Accession No. Y14735.1, accessed at http://www.ncbi.nlm.nih.gov/nuccore/Y14735, Aug. 19, 1998, 3 pages. [cited by applicant]
George, et al., “Profile of Efraloctocog Alfa and its Potential in the Treatment of Hemophilia A”, Journal of Blood Medicine, vol. 6, pp. 131-141, Apr. 24, 2015. [cited by applicant]
Geraghty, S., et al., “Practice patterns in haemophilia A therapy—global progress towards optimal care,” Haemophilia 12(1):75-81, Blackwell Publishing Ltd., England (2006). [cited by applicant]
Gitschier, J., et al., “Characterization of the human factor VIII gene,” Nature 312(5992):326-330, Nature Publishing Group, England (1984). [cited by applicant]
Gouw et al., (2013), “Factor VIII products and inhibitor development in severe hemophilia A”, N Engl J Med, 368(3): 231-239, doi: 10.1056/NEJMoa1208024. [cited by applicant]
Gouw et al., “Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment”, Haemophilia, May 2009, 15(3): 712-717. [cited by applicant]
Graham, J.B., et al., “Canine Hemophilia: Observations on the Course, the Clotting Anomaly, and the Effect of Blood Transfusions,” The Journal of Experimental Medicine 90(2):97-111, The Rockefeller University Press, Uni… [cited by applicant]
Green, D., “Factor VIII inhibitors: a 50-year perspective,” Haemophilia 17(6):831-838, Blackwell Publishing Ltd., England (Nov. 2011). [cited by applicant]
Gringeri et al., “Immune tolerance induction with high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response”, Haemophilia, Jul. 2007, 13(4): 373… [cited by applicant]
Gringeri, (2007) “VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study”, Haemophilia, 13(Suppl 5): 73-77, doi:10.1111/j.1365-2516.2007.01579.x. [cited by applicant]
Grubb, J.H., et al., “Infused Fc-tagged β-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice,” Proceedings of the National Academy of Sciences USA 105(24)8375… [cited by applicant]
Gupta et al., (2015) “Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance”, Sci Transl Med, 7(275): 275ra221, doi:10.1126/scitranslmed.aaa1957. [cited by applicant]
Hacker, M.R., et al., “Barriers to compliance with prophylaxis therapy in haemophilia,” Haemophilia 7(4):392-396, Blackwell Science, England (2001). [cited by applicant]
Hay et al., (2012) “The principal results of the International Immune Tolerance Study: a randomized dose comparison”, Blood, 119(6): 1335-1344, doi:10.1182/blood-2011-08-369132. [cited by applicant]
Hay et al., “The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization,” British Journal of Haematology 133(6):591-605, Blackwell Publishi… [cited by applicant]
Haya et al., (2001) “Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry”, Haemophilia, 7(2): 154-159. [cited by applicant]
Healey, J.F., et al., “The cDNA and derived amino acid sequence of porcine factor VIII,” Blood 88(11):4209-4214, The American Society of Hematology, United States (1996). [cited by applicant]
Herzog, R.W., et al., “Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector,” Nature Medicine 5(1):56-63, Nature Publishing Co., United St… [cited by applicant]
Huang, C., “Receptor-Fc Fusion Therapeutics Traps, and MIMETIBODYTM Technology,” Current Opinion in Biotechnology 20(6):692-699, Current Biology, England (2009). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/021332, mailed Mar. 18, 2013. [cited by applicant]
Ishiguro, “Immune Mechanisms Involved in the Development and Eradication of Anti-Factor VIII Alloantibodies in Hemophilia”, Japanese Journal of Clinical Immunology, vol. 34, Issue 6, pp. 476-484, 2011. [cited by applicant]
Jimenez-Yuste et al., (2016) “Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study”, Haemophilia, 22(6)… [cited by applicant]
Karpf, D.M., et al., “Preclinical pharmacokinetic (PK) evaluation of glycopegylated long acting RFVIII,” Hemophilia 16(Suppl. 4):40 Blackwell Publishing Ltd., England (2010). [cited by applicant]
Kasper C.K., “Diagnosis and Management of Inhibitors to Factors VIII and IX: An Introductory Discussion for Physicians,” Treatment of Hemophilia 34:1-22, World Federation of Hemophilia, Canada (2004). [cited by applicant]
Kau, et al., “Anti-Interleukin 4 and 13 for Asthma Treatment in the Era of Endotypes”, Current Opinion in Allergy and Clinical Immunology, vol. 14, No. 6, pp. 570-575, Dec. 2014. [cited by applicant]
Kempton et al., (2014) “Toward optimal therapy for inhibitors in hemophilia”, Blood, 124(23): 3365-3372, doi:10.1182/blood-2014-05-577643. [cited by applicant]
Kreuz et al., (2016) “First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction… [cited by applicant]
Kreuz, et al., “Immune Tolerance Therapy in Paediatric Haemophiliacs with Factor VIII Inhibitors: 14 Years Follow-up”, Haemophilia, vol. 1, No. 1, pp. 24-32, Jan. 1, 1995. [cited by applicant]
Kreuz, W., et al., “When should prophylactic treatment in patients with haemophilia A and B start? —The German experience,” Haemophilia 4(4):413-417, Blackwell Science Ltd., England (1998). [cited by applicant]
Kroner et al. (1999) “Comparison of the international immune tolerance registry and the North American immune tolerance registry”, Vox Sang, 77(Suppl 1): 33-37. [cited by applicant]
Kurth et al., (2011) “The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience”, J Thromb Haemost, 9(11): 2229-2234, doi: 10.1111/j… [cited by applicant]
Lee, C.A., et al., “Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One- Stage Clotting and Chromogenic Factor VIII Assay,” Thrombosis and Haemostasis 82(6):1644-1647, Schattauer Verlag, Germany (1999). [cited by applicant]
Lei, T.C., “Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins,” Blood 105(12):4865-4870, The American Society of Hematology… [cited by applicant]
Lencer, W.I. and Blumberg, R.S., “A passionate kiss, then run: exocytosis and recycling of lgG by FcRn,” TRENDS in Cell Biology 15(1):5-9, Elsevier Science Publishers, England (2005). [cited by applicant]
Lenting, P.J., et al., “Clearance mechanisms of von Willebrand factor and factor VIII,” Journal of Thrombosis and Haemostasis 5(7):1353-1360, Blackwell Publishing, England (2007). [cited by applicant]
Liesner, R.J., et al., “The impact of prophylactic treatment on children with severe haemophilia,” British Journal of Haematology 92(4):973-978, Blackwell Publishing, England (1996). [cited by applicant]
Lillicrap, D., “Improvements in factor concentrates,” Current Opinion in Hematology 17(5):393-397, Lippincott Williams & Wilkins, United States (2010). [cited by applicant]
Ling, et al., “Classification of the Kinetics of Factor VIII Inhibitors in Haemophilia A: Plasma Dilution Studies Are More Discriminatory Than Time-Course Studies”, British Journal of Haematology, vol. 114, No. 4, pp. 8… [cited by applicant]
Liu, T. Z., et al. “Recombinant FVIII Fc fusion protein is fully active in treating acute injury and demonstrates prolonged prophylactic efficacy in hemophilia A mice,” Journal of Thrombosis and Haemostasis 9(Supp.2):56… [cited by applicant]
Liu, T., et al., “Evaluation of antibody responses to rFVIIIFc compared to Xyntha® and Advate® in hemophilia A mice,” Hemophilia 18(Suppl. 3):41, Blackwell Publishing Ltd., England (Jul. 9, 2012). [cited by applicant]
Liu, T., et al., “Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in Hemophilia A Dogs,” 50th ASH Annual Meeting and Exposition Online Program and Ab… [cited by applicant]
Livak, K.J. and Schmittgen T.D., “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method,” Methods 25(4):402-408, Academic Press, United States (2001). [cited by applicant]
Ljung, R.C.R., “Prophylactic treatment in Sweden—overtreatment or optimal model?” Haemophilia 4(4):409-412, Blackwell Science Ltd., England (1998). [cited by applicant]
Löfqvist, et al., “Haemophilia Prophylaxis In Young Patients ± A Long-Term Follow-Up”, Journal of Internal Medicine, vol. 241, pp. 395-400, 1997. [cited by applicant]
Lollar, P. and Parker, E.T., “Structural Basis for the Decreased Procoagulant Activity of Human Factor VIII Compared to the Porcine Homolog,” Journal of Biological Chemistry 266(19):12481-12486, The American Society for… [cited by applicant]
Lollar, P., et al., “Coagulant Properties of Hybrid Human/Porcine Factor VIII Molecules,” Journal of Biological Chemistry 267(33):23652-23657, The American Society for Biochemistry and Molecular Biology, Inc., United St… [cited by applicant]
Lozier, J.N., et al., “The Chapel Hill Hemophilia A Dog Colony Exhibits a Factor VIII Gene Inversion,” Proceedings of the National Academy of Sciences USA 99(20):12991-12996, The National Academy of Sciences, United Sta… [cited by applicant]
Manco-Johnson, M., et al., “Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia,” New England Journal of Medicine 357(6):535-544, Massachusetts Medical Society, United States (2… [cited by applicant]
Mariani et al., “Immune tolerance induction in hemophilia A: a review”, Semin Thromb Hemost., Feb. 2003, 29(1): 69-76. [cited by applicant]
McCue, J.T., et al., “Applicants of a Novel Affinity Adsorbent for the Capture and Purification of Recombinant Factor VIII Compounds,” Journal of Chromatography A 1216(45):7824-7830, Elsevier, Netherlands (2009). [cited by applicant]
Meslier, Y., et al., “Induction of Tolerance to Therapeutic FVIII by Materno-Fetal Transfer in a Hemophilia A mouse model,” European Journal Immunology 2009: Tuesday, Poster Sessions, abstract PD11/26, p. S536, Wiley-VC… [cited by applicant]
Metzner, H.J., et al., “Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis,” Haemophilia 4(Suppl. 3):25-32, Blackwell Science Ltd., Engl… [cited by applicant]
Metzner, H.J., et al., “Genetic fusion to albumin improves the pharmacokinetic properties of factor IX,” Journal of Thrombosis and Haemostasis 102(4):634-644, Stuttgart, Schattauer, Germany (2009). [cited by applicant]
Mikaelsson, M. and Oswaldsson, U., “Assaying the Circulating Factor VIII Activity in Hemophilia A Patients Treated with Recombinant Factor VIII Products,” Seminars in Thrombosis and Hemostasis 28(3):257-264, Thieme, Uni… [cited by applicant]
Molho, P., et al., “Epidemiological survey of the orthopaedic status of severe hemophilia A and B patients in France,” Haemophilia 6(1):23-32, Blackwell Science Ltd., England (2000). [cited by applicant]
Morfini, M., “Pharmacokinetics of factor VIII and factor IX,” Hemophilia 9(Suppl. 1):94-100, Blackwell Publishing Ltd., England (2003). [cited by applicant]
Møss, J., et al., “Safety and pharmacokinetic of a glycoPEGylated recombinant activated factor VIII derivative: a randomized first human dose trial in healthy subjects,” Journal of Thrombosis and Haemostasis 9(7):1368-1… [cited by applicant]
Nakar et al., (2015) “Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres”, Haemophilia, 2… [cited by applicant]